# The oral detour through Route 66 Peptides

> Route 66 Peptides explores the chemistry of the oral route: ipamorelin-derived molecules, dog absorption studies and the trade-offs in hormone selectivity.

**Molecules in transit**

An easier entrance can demand a different molecule. I followed ipamorelin into the chemistry of getting a related compound through the gut.

## Oral absorption in dogs

The road in this story begins with a chemical redesign. An ipamorelin-derived series achieved [oral bioavailability of 10–55% in dogs](https://pubmed.ncbi.nlm.nih.gov/9733496/) while retaining growth-hormone-releasing activity in cell and animal tests. Bioavailability is the fraction of an administered dose that reaches circulation. The researchers were changing the compounds to make that passage possible.

I admire the stubbornness of that project. An easier way into the body sounds like a packaging decision until the molecule itself has to be rebuilt. The dog findings make the oral route interesting on its own terms: a problem in medicinal chemistry, with a family of related candidates at the end of it.

> The oral percentages describe derived compounds tested in dogs. The original peptide supplied the starting design.

## A different hormonal profile

Cortisol sent this journey off in another direction. The [animal characterization of the oral derivative NN703](https://pubmed.ncbi.nlm.nih.gov/10427162/) reported 30% oral bioavailability in beagle dogs. It also reported a 50% cortisol increase across the tested doses, without a dose-dependent pattern. That hormonal result complicates the appealing story of easier entry.

Compare the parent peptide's [acute characterization in rat pituitary cells, rats and swine](https://pubmed.ncbi.nlm.nih.gov/9849822/): ipamorelin released growth hormone without raising ACTH or cortisol above the response seen with growth-hormone-releasing hormone. I would grant that advantage only to the compound and experiment that earned it. Each alteration earns its own examination.

## Articles

The [oral analogue studies](/oral-analogues) follow the candidates through the dog experiments. At the [molecular workshop](/molecular-workshop), the changes become more physical: hybrids, a chain's terminal region and restrictions on its shape. The [hormone-selectivity page](/hormone-selectivity) puts the cortisol observation beside the parent peptide's earlier result.

I also want a destination beyond circulation. The [human studies](/human-studies) return to intravenous ipamorelin, a growth-hormone pulse and a trial after bowel surgery. The research questions change along that stretch of road.

## The human studies

In healthy male volunteers, intravenous ipamorelin produced [a single growth-hormone pulse and an approximately 2-hour terminal half-life](https://pubmed.ncbi.nlm.nih.gov/10496658/). A separate [trial in adults undergoing bowel resection missed its main meal-tolerance endpoint](https://pubmed.ncbi.nlm.nih.gov/25331030/). These studies give the parent peptide a human record; the oral derivatives have the preclinical record described above.

The ingenuity here wins me over: getting a molecule across a difficult boundary. Whether that ingenuity produces a useful treatment remains a further question, and the bowel-surgery result leaves plenty to argue about.

---

Route 66 Peptides is my roadside notebook of published research, an editorial project with no sales or medical advice.